Controlled Release Drug Delivery Systems and Design

Posted on Oct 2, 2026 in Biotechnology

Approaches to Design Controlled Release Formulations

These are the methods or processes by which we design Controlled Release Drug Delivery Systems (CRDDS):

  • 1. Diffusion-controlled release
  • 2. Dissolution-controlled release
  • 3. Ion-exchange controlled release

1) Diffusion-Controlled Release System

Diffusion is the process of movement of drug molecules from a higher concentration to a lower concentration during absorption. For CRDDS, we can control the diffusion process by using polymers. Before polymer coating, drugs are enclosed with a rate-controlling membrane which controls the delivery rate.

Types of Systems:

i) Reservoir System (Membrane Controlled): In this system, a water-insoluble polymeric material encloses a core of drug which controls the release rate. Polymers used in such devices include ethyl cellulose and polyvinyl acetate.

ii) Matrix System (Monolithic): In this system, drug molecules are homogeneously dispersed in a rate-controlling insoluble matrix (ethyl cellulose). This matrix is prepared by using beeswax, carnauba wax, and hydrogenated castor oil. These matrices can control the release of the drug. Some hydrophilic matrices are also used, e.g., HPMC, HPC, Xanthan gum, etc. It follows first-order kinetics.

dm/dt = (A · D · K · ΔC) / L

  • A = Area
  • D = Diffusion coefficient
  • K = Partition coefficient between drug and membrane
  • ΔC = Concentration difference across membrane
  • L = Diffusion length path

2) Dissolution-Controlled Release

Dissolution is a process in which drug particles are dissolved in a solvent (stomach fluid in the case of the body) and then absorbed into the blood. For the development of CRDDS, we can control this dissolution process using polymers by decreasing the rate of dissolution through two main ways:

i) Encapsulation / Reservoir Dissolution Controlled: In this method, particles or granules of the drug are coated individually with a slowly dissolving polymer, and these coated particles are compressed into a tablet or pellets and placed in a capsule. Drug release is determined by the dissolution rate.

ii) Matrix Dissolution Controlled: Examples include Chlorthalidone, Pantoprazole, etc. This involves the compression of the drug with a slowly dissolving carrier into a tablet. They control dissolution by altering the porosity of the tablet, decreasing wettability, and dissolving at a slower rate. Polymers used include ethyl cellulose and various waxes.

dC/dt = (D · S / H) * (Cs – C)

Where:

  • dC/dt = Rate of dissolution
  • D = Diffusion coefficient of the drug
  • S = Effective surface area
  • Cs = Saturation solubility
  • C = Concentration of drug in solution in GI fluid

3) Ion-Exchange Controlled Release

This system is used to control the release of an ionizable drug complexed with an ion-exchange resin—e.g., sodium polystyrene sulfonate. It has two types:

  1. Cationic drug complexed with a resin containing SO₃⁻ group: Resin-SO₃⁻Drug⁺ + H⁺ → Resin-SO₃H + Drug⁺
  2. Anionic drug complexed with a resin containing N(CH₃)₂ group

Factors Affecting CRDDS Design

1) Physicochemical Properties

These are factors or parameters related to the drug itself:

  • i) Routes of administration: The most suitable routes for CRDDS are oral, parenteral, and sometimes transdermal and mucosal/adhesive.
  • ii) Molecular size: For CRDDS, the molecular size of drugs should be small for better coating (by polymer) and absorption.
  • iii) Aqueous solubility: Required drugs must have good solubility (not extremely high water solubility, otherwise it causes a rapid dissolution rate, and not too low).
  • iv) Partition coefficient: Drugs can be lipophilic or hydrophilic. With the help of the partition coefficient, we find the drug’s affinity for membranes.
  • v) Mechanism & site of absorption: For CRDDS, carrier-mediated transport mechanisms are generally not suitable (e.g., Vitamin B).
  • vi) Drug Stability: The drug should have good stability in GI fluids. Drugs with stability issues in any particular part of the GIT are poor candidates.
  • vii) Drug pKa: It defines the dissociation of the drug, i.e., ionic or non-ionic (unionized). Highly ionized drugs are poor candidates for CRDDS, whereas unionized forms undergo appropriate absorption.

2) Biological Properties

These are factors or parameters related to the body:

  • i) Absorption: Drugs should have good absorption. Drugs with poor absorption are not suitable for CDDS & SEDDS.
  • ii) Distribution: Distribution should be favorable, while drug disposition must be considered during formulation.
  • iii) Protein Binding: Refers to the formation of a complex of drug with proteins. High protein binding decreases the distribution and absorption of the drug; therefore, low-to-moderate protein binding is preferred.
  • iv) Elimination / Biological half-life: Drugs with a slow elimination rate and a large half-life maintain therapeutic blood levels for extended time periods.
  • v) Metabolism: Drugs undergoing extensive hepatic first-pass metabolism or intestinal metabolism are generally not considered for CDDS & SDDS.
  • vi) Therapeutic Index (T.I.): It is the margin of safety between the minimum effective dose and the minimum tolerated/toxic dose.

Polymer Classification in Drug Delivery

1. Based on the Source (Origin)

  • Natural Polymers: Also known as biopolymers, obtained naturally. Examples: Gelatin, Albumin, Collagen, Natural Rubber, Cellulose, Protein, Starch, etc.
  • Semi-Synthetic Polymers: Prepared by chemically modifying natural polymers whose physical properties are altered. Examples: Polylactic acid, Methyl cellulose, Polyglycolic acid (PGA), etc.
  • Synthetic Polymers: Prepared in the laboratory; known as man-made polymers. Examples: HPC, HPMC, Methyl cellulose, etc.

2. Based on Polymerization

Process by which polymers are formed:

  • Addition Polymers: Polymers are formed by the addition of one monomer molecule with another monomer molecule. Examples: Polyethylene, Polystyrene, etc. (Homopolymer). Production of polyethylene from ethene and polypropylene from propene.
  • Condensation Polymers: Polymers are produced by a condensation polymerization process in which intermolecular reactions occur between bifunctional or polyfunctional monomer molecules that have reactive functional groups.

3. Based on Degradability

  • Non-biodegradable Polymers: These polymers do not undergo natural degradation in the body. Examples: Polyethylene, Ethyl cellulose (EC), Polyvinyl chloride (PVC), Polyethylene vinyl acetate (EVA), etc.
  • Biodegradable Polymers: These polymers undergo natural degradation in the body. Examples: Polylactic acid (PLA), Polyglycolic acid (PGA), etc.

4. Based on Structure

  • Linear Polymers: Monomers are linked with one another to make a long straight chain (High density + tensile strength). Examples: Polyethylene, PVC, Nylon, Polyester, etc.
  • Branched Chain Polymers: The polymers possess a straight long chain having different side chains (Low density + tensile strength). Examples: Polypropylene.
  • Cross-linked or Network Polymers: Two linear chains are joined to each other through covalent bonds. Examples: Bakelite, Melamine-formaldehyde resins, Vulcanized rubber, etc.

Ideal Properties of a Polymer

  • Inert and compatible with the environment
  • Non-toxic
  • Easy to administer
  • Easy and inexpensive to produce
  • Good mechanical strength

Applications of Polymers in CRDDS

Polymers are the most promising options for CRDDS because they provide slow or controlled drug release.

  • Controlled Release Dosage Forms: Reservoir system, Matrix system, Swelling control drug delivery (e.g., Ocusert system), pH responsive systems
  • Immediate Release Dosage Forms: Tablets (Film coating), Capsules (Gelatin shell)
  • Sustained Release Dosage Forms
  • Extended Release Dosage Forms
  • Modified Release Dosage Forms
  • Gastroretentive Dosage Forms

Implantable Drug Delivery Systems

Implantable drug delivery systems allow targeted and localized drug delivery and may achieve a therapeutic effect with lower concentrations of drugs. As a result, they may minimize potential side effects of therapy while offering the opportunity for increased patient compliance. This type of system also has the potential to deliver drugs which would normally be unsuitable orally because it avoids first-pass metabolism and chemical degradation in the stomach and intestine, thus increasing bioavailability.

Concept of Implants

1. In situ forming implants (In situ depot forming systems)

(a) In situ precipitating implants

These implants are formed from a drug contained in a biocompatible solvent. The polymer solution forms implants after subcutaneous (s.c.) or intramuscular (i.m.) injection and contact with aqueous body fluids via the precipitation of polymers. In situ precipitating implants are formulated to overcome some problems associated with the use of biodegradable microparticles:

  • i) Requirement for reconstitution before injection.
  • ii) Inability to remove the dose once injected.
  • iii) Relatively complicated manufacturing procedures to produce a sterile, stable, and reproducible product.